Future impact of sight loss

Article

A study by the Royal National Institute of Blind People (RNIB) on the prevalence and costs of sight loss estimates that 1.8 million people with partial sight and blindness lived in the UK in 2008.

A study by the Royal National Institute of Blind People (RNIB) on the prevalence and costs of sight loss estimates that 1.8 million people with partial sight and blindness lived in the UK in 2008. It found that 53.5% was due to refractive error, 16.7% AMD, 13.7% cataract, 5.3% glaucoma, 3.5% diabetic retinopathy, and 7.4% due to other eye diseases.

The study, which comprises two pieces of research undertaken by Access Economics and EpiVision, will support and inform the UK Vision Strategy and RNIB’s strategic goals.

EpiVision found that between 2010 and 2020, prevalence in the UK adult population of sight loss due to AMD will have risen by 31%, cataracts by 20%, diabetic retinopathy by 16% and glaucoma by 25%. However, among people of African-Caribbean origin there is predicted to be a 57% increase in sight loss due to glaucoma, over the decade.

Looking at direct costs to the health care system and indirect costs, such as unemployment due to sight loss, Access Economics calculates the total economic cost of sight problems in the UK during 2008 to be £6.5 billion. While further findings predict that by 2050 the numbers of people with partial sight and blindness in the UK will more than double, to nearly 4 million people.

In addition to studying the current costs of sight loss, the research considers the impact of expected future improvements in prevention and treatment, on the prevalence and costs of AMD and other conditions.

Future Sight Loss UK also looks at the cost-effectiveness of a number of interventions for preventing and treating sight loss.

These studies suggest that the most cost-effective intervention is expected to be one targeting minority ethnic groups, who are expected to have lower access to eye care services than the general population and more severe cases of undetected eye disease.

Lesley-Anne Alexander, chief executive of RNIB and chairman of the UK Vision Strategy strategic advisory group, says: “This report provides incredibly valuable data to drive the UK Vision Strategy and RNIB’s work to ensure those most at risk of sight loss have the benefit of high quality and timely intervention.

“The cost of sight loss, both direct and indirect, cannot be understated, though it is something that can be managed effectively. The right steps need to be taken now to avoid unnecessary sight loss and help those who have already lost their sight get the support they need to live full, independent lives.”

The research briefing on Future Sight Loss UK is available from www.rnib.org.uk/futuresightlossuk

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Christine Curcio, PhD, of the University of Alabama at Birmingham Heersink School of Medicine, shares histology update and revised nomenclature for OCT with Sheryl Stevenson of the Eye Care Network and Ophthalmology Times
SriniVas R. Sadda, MD, FARVO, shares key points from his retina presentation at the International SPECTRALIS Symposium
Robert Sergott, MD, describes fluorescence lifetime imaging ophthalmoscopy (FLIO) and the International SPECTRALIS Symposium – And Beyond (ISS) in Heidelberg, Germany.
Rayaz Malik, MBChB, PhD, a professor of medicine at Weill Cornell Medicine - Qatar, spoke with Ophthalmology Times Europe about his presentation. It's titled "An eye on neurodegenerative diseases: Challenging the dogma" at the International SPECTRALIS Sympsoium. In conversation with Hattie Hayes, Ophthalmology Times Europe
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Rayaz Malik, MBChB, PhD, shares his presentation, titled An eye on neurodegenerative diseases: Challenging the dogma, at this year's International SPECTRALIS Symposium
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
© 2025 MJH Life Sciences

All rights reserved.